Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: A bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats

Neuroscience

Volumn 159, Issue 1, 2009, Pages 16-20

  Buck, K ^a   Ferger, B ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

dyskinesia; in vivo microdialysis; intrastriatal; l DOPA; noradrenaline; Parkinson's disease

Indexed keywords

BENSERAZIDE; LEVODOPA; NORADRENALIN; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DYSKINESIA; EXPERIMENTAL RAT; IN VIVO STUDY; LIMB MOVEMENT; MALE; MEDIAL FOREBRAIN BUNDLE; MICRODIALYSIS; MOUTH; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TONGUE; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; BENSERAZIDE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MALE; MICRODIALYSIS; NOREPINEPHRINE; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX;

EID: 60349090799     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.12.026     Document Type: Article

References (29)

1. Alachkar A., Brotchie J., and Jones O.T. alpha2-Adrenoceptor-mediated modulation of the release of GABA and noradrenaline in the rat substantia nigra pars reticulata. Neurosci Lett 395 2 (2006) 138-142
2. Brotchie J.M. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 20 8 (2005) 919-931
3. Buck K., and Ferger B. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats. Neurobiol Dis 29 2 (2008) 210-220
4. Carta M., Lindgren H.S., Lundblad M., Stancampiano R., Fadda F., and Cenci M.A. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 96 6 (2006) 1718-1727
5. Colosimo C., and Craus A. Noradrenergic drugs for levodopa-induced dyskinesia. Clin Neuropharmacol 26 6 (2003) 299-305
6. Dekundy A., Lundblad M., Danysz W., and Cenci M.A. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179 1 (2007) 76-89
7. Fornai F., di Poggio A.B., Pellegrini A., Ruggieri S., and Paparelli A. Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Curr Med Chem 14 22 (2007) 2330-2334
8. Fox S.H., Henry B., Hill M.P., Peggs D., Crossman A.R., and Brotchie J.M. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 16 4 (2001) 642-650
9. Gomez-Mancilla B., and Bedard P.J. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 16 5 (1993) 418-427
10. Grondin R., Hadj T.A., Doan V.D., Ladure P., and Bedard P.J. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 361 2 (2000) 181-186
11. Henry B., Fox S.H., Peggs D., Crossman A.R., and Brotchie J.M. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 14 5 (1999) 744-753
12. Holmberg M., Scheinin M., Kurose H., and Miettinen R. Adrenergic alpha2C-receptors reside in rat striatal GABAergic projection neurons: comparison of radioligand binding and immunohistochemistry. Neuroscience 93 4 (1999) 1323-1333
13. Kubrusly R.C., Ventura A.L., de Melo Reis R.A., Serra G.C., Yamasaki E.N., Gardino P.F., de Mello M.C., and de Mello F.G. Norepinephrine acts as D1-dopaminergic agonist in the embryonic avian retina: late expression of beta1-adrenergic receptor shifts norepinephrine specificity in the adult tissue. Neurochem Int 50 1 (2007) 211-218
14. Lanau F., Zenner M.T., Civelli O., and Hartman D.S. Epinephrine and norepinephrine act as potent agonists at the recombinant human dopamine D4 receptor. J Neurochem 68 2 (1997) 804-812
15. Linazasoro G., Van Blercom N., Ugedo L., and Ruiz Ortega J.A. Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors?. J Neural Transm 1153 (2008) 431-441
16. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., and Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15 1 (2002) 120-132
17. McCune S.K., Voigt M.M., and Hill J.M. Expression of multiple alpha adrenergic receptor subtype messenger RNAs in the adult rat brain. Neuroscience 57 1 (1993) 143-151
18. Mela F., Marti M., Dekundy A., Danysz W., Morari M., and Cenci M.A. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 101 2 (2007) 483-497
19. Nagatsu T., and Sawada M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl 72 (2007) 113-120
20. Newman-Tancredi A., Audinot-Bouchez V., Gobert A., and Millan M.J. Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors. Eur J Pharmacol 319 2-3 (1997) 379-383
21. Nicholas A.P., Hokfelt T., and Pieribone V.A. The distribution and significance of CNS adrenoceptors examined with in situ hybridization. Trends Pharmacol Sci 17 7 (1996) 245-255
22. Onali P., Olianas M.C., and Gessa G.L. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum. Mol Pharmacol 28 2 (1985) 138-145
23. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1998), Academic Press, San Diego
24. Rascol O., Arnulf I., Peyro-Saint P.H., Brefel-Courbon C., Vidailhet M., Thalamas C., Bonnet A.M., Descombes S., Bejjani B., Fabre N., Montastruc J.L., and Agid Y. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 16 4 (2001) 708-713
25. Rommelfanger K.S., and Weinshenker D. Norepinephrine: The redheaded stepchild of Parkinson's disease. Biochem Pharmacol 74 2 (2007) 177-190
26. Savola J.M., Hill M., Engstrom M., Merivuori H., Wurster S., McGuire S.G., Fox S.H., Crossman A.R., and Brotchie J.M. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 18 8 (2003) 872-883
27. Schapira A.H. Present and future drug treatment for Parkinson's disease. J Neurol Neurosurg Psychiatry 76 11 (2005) 1472-1478
28. Tarazi F.I., Kula N.S., and Baldessarini R.J. Regional distribution of dopamine D4 receptors in rat forebrain. Neuroreport 8 16 (1997) 3423-3426
29. Zhang W., and Ordway G.A. The alpha2C-adrenoceptor modulates GABA release in mouse striatum. Brain Res Mol Brain Res 112 1-2 (2003) 24-32